Literature DB >> 26794821

Telemedicine Home Program in Patients with Cystic Fibrosis: Results after 10 Years.

F Murgia1, F Bianciardi1, T Solvoll2, I Tagliente3, F Bella4, A Carestia1, S Bella1.   

Abstract

OBJECTIVES: We studied the effect of Telehomecare (THC) in a group of cystic fibrosis (CF) patients.
MATERIALS AND METHODS: Forced Expiratory Volume in the first second (FEV1) was monitored at home, with the aim of an early recognition of the relapses of pulmonary infections. FEV1 was monitored for 4.5 years, using THC as a tool, in addition to the standard therapeutic protocol. 16 CF patients were followed by doctors experts in the treatment of CF, over a period of 4.5 years. We compared a control group among patients seen in the past for an identical period, matching for number, age, sex, respiratory function, bacterial colonization, O2 dependency, and complications. 16 CF patients with similar characteristics of age, degree of pulmonary involvement, bacterial colonization and O2 dependency. We calculated the annual mean values of FEV1 in both groups.
RESULTS: Spirometry data showed a significant improvement in annual Fev1 mean values for the THC patients as compared to the control group. DISCUSSION: The data are encouraging for a possible role of Telemedicine as a tool for domestic assistance of patients affected by chronic diseases, such as CF. However, reliable data on the long-term effectiveness of the use of THC in the treatment of CF patients is still lacking. The time has come to obtain reliable data through a multicenter collaboration study, also in order to standardize the international Telemedicine protocols.

Entities:  

Keywords:  Cystic fibrosis; FEV1; Medical device; Spirometry; Telehomecare; Telemedicine

Mesh:

Year:  2015        PMID: 26794821     DOI: 10.7417/T.2015.1905

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  5 in total

1.  Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results.

Authors:  Noah Lechtzin; Nicole Mayer-Hamblett; Natalie E West; Sarah Allgood; Ellen Wilhelm; Umer Khan; Moira L Aitken; Bonnie W Ramsey; Michael P Boyle; Peter J Mogayzel; Ronald L Gibson; David Orenstein; Carlos Milla; John P Clancy; Veena Antony; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

2.  Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting.

Authors:  Dana Albon; Lacrecia Thomas; Lindsay Hoberg; Sophia Stamper; Lindsay Somerville; Prigi Varghese; Ella Balasa; Matthew Roman; Maria T Britto; Melanie Miner; Emily Gehring; Clifford Gammon; Raouf S Amin; Michael Seid; Mike Powers
Journal:  BMJ Open Qual       Date:  2022-05

3.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.

Authors:  Brian L Graham; Irene Steenbruggen; Martin R Miller; Igor Z Barjaktarevic; Brendan G Cooper; Graham L Hall; Teal S Hallstrand; David A Kaminsky; Kevin McCarthy; Meredith C McCormack; Cristine E Oropez; Margaret Rosenfeld; Sanja Stanojevic; Maureen P Swanney; Bruce R Thompson
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

4.  A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF.

Authors:  Stephanie Thee; Mirjam Stahl; Rainald Fischer; Sivagurunathan Sutharsan; Manfred Ballmann; Axel Müller; Daniel Lorenz; Dominika Urbanski-Rini; Franziska Püschner; Volker Eric Amelung; Carola Fuchs; Marcus Alexander Mall
Journal:  BMC Pulm Med       Date:  2021-04-21       Impact factor: 3.317

5.  Telemonitoring in Cystic Fibrosis: A 4-year Assessment and Simulation for the Next 6 Years.

Authors:  Irene Tagliente; Leopoldo Trieste; Terje Solvoll; Fabrizio Murgia; Sergio Bella
Journal:  Interact J Med Res       Date:  2016-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.